The involvement of leptin and its receptor has been widely reported in many cancer types such as breast (Garofalo et al., 2006; Hu et al., 2002; Garofalo et al., 2004; Guo et al., 2012; Ishikawa et al., 2004; Gonzalez et al., 2006), colorectal (Yoon et al., 2004; Koda et al., 2007; Koda et al., 2007; Attoub et al., 2000) prostate (Frankenberry et al., 2004), gastric mucosa (Lee., 2014), esophagal (Beales et al., 2014), ovarian (Kato et., 2015), and endometrial (Sharma et al., 2006; Zhang et al., 2014) cancers. Here, LEP is linked to cancer.